Press coverage about Global Blood Therapeutics (NASDAQ:GBT) has trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Global Blood Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.6572123080766 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Global Blood Therapeutics, Inc. (GBT) Given a $53.00 Price Target by Oppenheimer Holdings, Inc. Analysts (americanbankingnews.com)
- Global Blood Therapeutics, Inc. (GBT) Given Overweight Rating at Morgan Stanley (americanbankingnews.com)
- Global Blood Therapeutics Makes a Bold Move (realmoneypro.thestreet.com)
- Critical Analysis: Global Blood Therapeutics (GBT) versus Caladrius Biosciences (CLBS) (americanbankingnews.com)
- Global Blood Therapeutics Inc. (GBT) has a value of $32.35 per share While Cytori Therapeutics, Inc. (CYTX) is stand … – Stocks Gallery (stocksgallery.com)
GBT has been the subject of several research reports. Oppenheimer Holdings, Inc. set a $53.00 target price on Global Blood Therapeutics and gave the company a “buy” rating in a research report on Wednesday. BidaskClub upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Wedbush reiterated an “ourperform” rating and issued a $73.00 target price on shares of Global Blood Therapeutics in a research report on Monday, September 18th. Cowen and Company reiterated an “outperform” rating and issued a $83.00 target price on shares of Global Blood Therapeutics in a research report on Monday, August 14th. Finally, Needham & Company LLC initiated coverage on Global Blood Therapeutics in a research report on Wednesday, September 20th. They issued a “buy” rating and a $51.00 target price for the company. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $54.08.
Shares of Global Blood Therapeutics (NASDAQ:GBT) traded up 0.76% during trading on Wednesday, hitting $33.20. The stock had a trading volume of 1,149,993 shares. The firm has a 50-day moving average price of $28.91 and a 200 day moving average price of $29.41. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $41.15. The company’s market capitalization is $1.45 billion.
Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.06. During the same period in the prior year, the business posted ($0.58) earnings per share. Equities analysts anticipate that Global Blood Therapeutics will post ($2.44) earnings per share for the current year.
In other news, insider Jung Choi sold 3,000 shares of the business’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now owns 140,055 shares of the company’s stock, valued at approximately $4,201,650. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Deval L. Patrick sold 27,053 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total value of $803,203.57. Following the completion of the sale, the director now directly owns 12,053 shares of the company’s stock, valued at approximately $357,853.57. The disclosure for this sale can be found here. In the last three months, insiders sold 36,053 shares of company stock valued at $1,073,204. 5.30% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Global Blood Therapeutics (GBT) Receiving Somewhat Positive Media Coverage, Report Shows” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.com-unik.info/2017/10/11/global-blood-therapeutics-gbt-receiving-somewhat-positive-media-coverage-report-shows.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
What are top analysts saying about Global Blood Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc. and related companies.